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Abstract
Intermediate-length CAG expansions (encoding 27–33 glutamines, polyQ) of the Ataxin2 
(ATXN2) gene represent a risk factor for amyotrophic lateral sclerosis (ALS). Recently, it has 
been proposed that ≥31 CAG expansions may influence ALS phenotype. We assessed whether 
ATXN2 intermediate-length polyQ expansions influence ALS phenotype in a series of 375 
patients of Sardinian ancestry. Controls were 247 neurologically healthy subjects, resident in the 
study area, age- and gender-matched to cases. The frequency of ≥31 polyQ ATNX2 repeats was 
significantly more common in ALS cases (4 patients vs. no control, p = 0.0001). All patients with 
≥31 polyQ repeats had a spinal onset versus 73.3% of patients with <31 polyQ repeats. Patients 
with an increased number of polyQ repeats have a shorter survival than those with <31 repeats (1.2 
vs. 4.2 years, p = 0.035). In this large series of ALS patients of Sardinian ancestry, we have found 
that ≥31 polyQ repeats of the ATXN2 gene influenced patients' phenotype, being associated to a 
spinal onset and a significantly shorter survival.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by a 
progressive loss of cortical, bulbar, and spinal motor neurons, leading to the loss motor 
function up to death due to respiratory failure. About half of patients have also various 
degrees of cognitive impairment, going from an overt frontotemporal dementia (FTD) to 
milder forms of executive or nonexecutive impairment (Montuschi et al., 2015 and Phukan 
et al., 2012). In most populations, about 10% of ALS patients have a family history for ALS, 
FTD, or both (familial ALS), whereas in the remaining no family history is detectable 
(sporadic ALS). However, in ALS patients of Sardinian ancestry, the frequency of family 
history for ALS or FTD is higher than in most Caucasian populations (Borghero et al., 2014, 
Chiò et al., 2011 and Orrù et al., 2012), with the only exception of Finland and Northern 
Sweden (Andersen et al., 1995 and Majounie et al., 2012). Moreover, ~40% of Sardinian 
ALS cases carry a pathogenic mutation, with several cases carrying 2 different mutations 
(Borghero et al., 2014).
Among disease-modifying genes in ALS, Ataxin 2 (ATXN2) is one of the most validated. 
Intermediate-length (CAG) expansions (encoding 27–33 glutamines, polyQ) represent a risk 
factor for ALS, increasing the risk of about 10 fold, and are a modifier of ALS clinical 
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presentation, being associated to a spinal phenotype and a more aggressive clinical course 
(Chiò et al., 2015).
The aim of this study was to assess the frequency of intermediate polyQ repeats in a series 
of patients of Sardinian ancestry and to analyze the clinical characteristics of these patients.
2. Methods
2.1. Patients
All ALS patients of Sardinian ancestry, defined as subjects with both parents of Sardinian 
origin, were eligible to be included in the study. Patients were identified between 2008 and 
2013 through the SARDINIALS and ITALSGEN consortia (Borghero et al., 2014, Chiò et 
al., 2011 and Chiò et al., 2012). Clinical information, including cognitive status, was 
collected on all patients. ALS patients met the EL Escorial revised criteria for definite, 
probable, probable laboratory-supported, or possible ALS (Brooks et al., 2000).
2.2. Controls
The 247 control individuals, all of Sardinian origin, included 115 women and 132 men and 
had a mean age of 62.1 years (standard deviation [SD] 14.5) at the time of blood collection. 
They were recruited through the Department of Public Health, Clinical and Molecular 
Medicine, University of Cagliari and the staff of Multiple Sclerosis Center—Azienda 
Sanitaria Locale 8 di Cagliari, as subjects without known history of a neurological disorder, 
such as nonblood-related companions or spouses of patients.
2.3. Mutational screening
Genomic DNA was isolated from peripheral blood lymphocytes using a standard protocol. 
The ATXN2 CAG repeat in exon 1 (Ref Seq NM_002973.3) was amplified using a 
fluorescent primer and sized by capillary electrophoresis on an ABI 3500×L genetic 
analyzer (Applied Biosystem, Foster City, CA, USA) (Cancel et al., 1997). The size standard 
used was the GeneScan 500 ROX dye and for analysis the GenMapper v.4.0 software. 
Receiver operating characteristics analysis showed that a cutoff ≥31 polyQ repeats in 
ATXN2 had the greatest sensitivity and specificity for discriminating ALS patients versus 
controls.
The following exons and 50 base-pair flanking intron-exon boundaries were also screened 
for mutations by polymerase chain reaction amplification, sequencing using the Big-Dye 
Terminator v3.1 kit (Applied Biosystems Inc), and analysis on an ABI Prism 3130 genetic 
analyzer: (1) all 5 coding exons of SOD1, (2) exon 6 of TARDBP, and (3) exons 14 and 15 
of FUS. These exons were selected as the vast majority of known pathogenic variants that lie 
within these mutational hotspots. A repeat-primed polymerase chain reaction assay was used 
to screen for the presence of the GGGGCC hexanucleotide expansion in the first intron of 
C9ORF72 (Dejesus-Hernandez et al., 2011 and Renton et al., 2011); a cutoff of ≥30 repeats 
combined with a typical sawtooth pattern was considered pathological.
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2.4. Standard protocol approvals, registrations, and patient consents
The study design was approved by the ethical committees of all the involved centers. 
Patients and controls signed written informed consent. The study was conducted in-line with 
the Italian ethical rules for data collection for statistical or scientific purposes and for data 
protection.
3. Results
The clinical and genetic characteristics of the ALS patients included in this study have been 
previously described elsewhere (Borghero et al., 2014). The size of the ATXN2 repeats in 
ALS patients compared to the control group is reported in Fig. 1. The most common alleles 
(22 and 23) were identified in 98.9% of controls' chromosomes and 95.9% of cases' 
chromosomes. ATXN2 repeats ≤30 were similarly distributed between ALS cases and 
controls, whereas those ≥31 were significantly more common in cases (4 cases and no 
controls, p = 0.0001) (Fig. 1). The second allele in patients with ≥27 repeats was 22 in all 
cases. The overall frequency of cases with ≥31 polyQ repeats in this Sardinian series of 
patients was 1.1%.
Overall, 155 patients (41.3%) carried a genetic mutation of one of the major ALS genes 
(Borghero et al., 2014). Three of 4 cases with ≥31 polyQ repeats were apparently sporadic 
and did not show any mutation of the examined ALS-related genes. The remaining case with 
≥31 polyQ repeats was a familial ALS case who also carried a p.T622A missense mutation 
of the MATR3 gene (pedigree ITALS#10) (Johnson et al., 2014); her first degree cousin, 
who also carried the MATR3 mutation, was homozygous for 22-22 repeats of the ATXN2 
gene; interestingly, the patient carrying the intermediate-length polyQ repeats died 33 
months after ALS onset, whereas her cousin, who does not carry the repeat expansion, is 
still alive 50 months after onset, although on nocturnal noninvasive ventilation.
Of the 59 patients with a GGGGCC hexanucleotide repeat expansion of the C9ORF72 gene, 
42 were homozygous for 22-22 repeats and 2 for 23-23 repeats, while the others were 
heterozygous (1 had 17–22 repeats, 1 had 21–22, and 13 had 22–23). None of them had >23 
repeats.
3.1. Clinical characteristics of patients with ≥31 polyQ repeats
The mean age at onset of patients with ≥31 polyQ repeats was 59.5 years (SD 7.0), only 
slightly younger than that of patients with <31 polyQ repeats (61.2 years [SD 12.1]) (p = 
0.78). All patients with ≥31 polyQ repeats had a spinal onset versus 73.3% of patients with 
<31 polyQ repeats (p = 0.58). The patients with ≥31 polyQ repeats had a significantly 
shorter median survival than that of patients with <30 polyQ repeats (1.2 years, interquartile 
range 0.9–2.7 vs. 4.2, interquartile range 2.2–10) (p = 0.035) (Fig. 2). The presence of polyQ 
repeats ≥31 remained independently significant as negative prognostic factor also at 
multivariable Cox analysis (data not shown).
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4. Discussion
In this large series of ALS patients of Sardinian ancestry, we have found that ≥31 polyQ 
repeats of the ATXN2 gene represent a significant risk for ALS. Moreover, ≥31 polyQ 
repeats influenced patients' phenotype, being associated to a spinal onset and a significantly 
shorter survival.
The frequency of intermediate-length polyQ repeats in Sardinian patients is lower than 
observed in continental Italy and southern Europe and similar to that of subjects of north 
European ancestry (Chiò et al., 2015). This finding is in keeping with the other genetic 
characteristics that differentiate Sardinians from continental Italians, such as the higher 
frequency of C9ORF72 mutations in ALS (Borghero et al., 2014) and the higher incidence 
of multiple sclerosis (Cocco et al., 2011), both comparable to the figures reported for 
northern Europe. Moreover, the frequency of SCA2 expansion patients in Sardinians is 
lower than in other Italian populations (unpublished data observed from the results of SCA2 
genetic tests performed since 2006 in the laboratory of the Regional Multiple Sclerosis 
Center of Cagliari).
In this series, we did not find any patient carrying the C9ORF72 expansion to have ATXN2 
intermediate-length polyQ repeats ≥27. This finding is in keeping with 2 cohorts of ALS 
patients from northern and central Italy (Chiò et al., 2015) but differs from another study 
(van Blitterswijk et al., 2014). It is possible that this difference is because of ethnic-based 
and highlights the importance of comparing large cohorts of patients of different origin.
The influence of ATXN2 intermediate-length polyQ repeats on ALS phenotype is intriguing. 
ALS cases with ≥31 polyQ repeats have more frequently a spinal onset and a have a 
significantly shorter survival than those without the expansion (Chiò et al., 2015). The 
mechanism of reduced survival in patients carrying ATXN2 intermediate-length polyQ 
repeats remains elusive. ATXN2 may act through several, nonmutually exclusive 
mechanisms, such as cytoplasmic aggregations of ATXN2 protein, aggregations of other 
proteins induced by abnormal polyQ expansions in ATXN2, defects in the endoplasmic 
reticulum-Golgi pathway, abnormal neuronal calcium signaling, and formation of nuclear 
RNA foci sequestering essential RNA-binding proteins (van den Heuvel et al., 2014).
We have shown that, in this cohort of Sardinian patients ATXN2 intermediate-length polyQ 
repeats represent a risk factor for ALS and negatively influence its prognosis. These findings 
support the idea that ATXN2 may represent a promising therapeutic target in ALS.
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Fig. 1. 
Distribution of ATXN2 polyQ repeat lengths in amyotrophic lateral sclerosis (ALS) and 
control cases. In the insert, data bout cases and controls with ≥27 repeats are magnified. 
PolyQ lengths ≥31 are significantly more frequent in ALS cases (p = 0.0001) (red, ALS 
patients; blue, controls).
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Fig. 2. 
Kaplan-Meier survival estimation from onset to death and/or tracheostomy. Blue line, <31 
polyQ repeats; green line, ≥31 polyQ repeats. p = 0.035.
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